The Effect of an Oral Medicine on Nausea and Vomiting Caused by Chemotherapy in Children With Cancer.

Evaluation the Effect of Olanzapine on the Nausea and Vomiting Induced by Chemotherapy in Children with Malignancy.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150119020715N6

Enrollment

Registered

2018-06-23

Start date

2018-05-21

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting. Nausea and vomiting

Interventions

Intervention 1: Intervention group: 5 mg olanzapine tablets are used at a dose of 0.1 mg / kg PO per 24 hours (based on the weight at a maximum dose of 10 mg per day). Intervention 2: Control group: S

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children aged 5 to 15 years of age who have recently diagnosed as malignancy Indication of chemotherapy, based on assessment, diagnosis and approval by physician On the first day of chemotherapy, they should have a RAS score more than 20.

Exclusion criteria

Exclusion criteria: Diseases that triggers the nausea and vomiting Inability to express the severity of nausea and vomiting Patients who has not satisfied with the study Olanzapine drug complications

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: Before starting chemotherapy, 24 hours after chemotherapy and 5 days after chemotherapy. Method of measurement: To evaluate the state of nausea and vomiting in patients, RAS criteria will be used to measure the state of nausea and vomiting in patients from 1 to 100.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAziz Eghbali

Arak University of Medical Sciences

dr.eghbali@arakmu.ac.ir+33 135075

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026